These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22490049)

  • 1. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
    Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
    SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors.
    Pinar A; Yurdakul P; Yildiz I; Temiz-Arpaci O; Acan NL; Aki-Sener E; Yalcin I
    Biochem Biophys Res Commun; 2004 Apr; 317(2):670-4. PubMed ID: 15063810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
    Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
    Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
    Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
    J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR study on heterocyclic topoisomerase II inhibitors using CoMSIA.
    Tekiner-Gulbas B; Temiz-Arpaci O; Yildiz I; Aki-Sener E; Yalcin I
    SAR QSAR Environ Res; 2006 Apr; 17(2):121-32. PubMed ID: 16644553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
    Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
    Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
    Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
    Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
    Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
    Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S
    Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.
    Na Y; Nam JM
    Bioorg Med Chem Lett; 2011 Jan; 21(1):211-4. PubMed ID: 21115246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
    Karki R; Park C; Jun KY; Jee JG; Lee JH; Thapa P; Kadayat TM; Kwon Y; Lee ES
    Eur J Med Chem; 2014 Sep; 84():555-65. PubMed ID: 25062006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
    Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
    Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor agents. Part 235: Novel 4'-ester etoposide analogues as potent DNA topoisomerase II inhibitors with improved therapeutic potential.
    Xiao Z; Vance JR; Bastow KF; Brossi A; Wang HK; Lee KH
    Bioorg Med Chem; 2004 Jun; 12(12):3363-9. PubMed ID: 15158805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.
    Lage H; Aki-Sener E; Yalcin I
    Int J Cancer; 2006 Jul; 119(1):213-20. PubMed ID: 16450374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents.
    Kamal A; Suresh P; Ramaiah MJ; Srinivasa Reddy T; Kapavarapu RK; Rao BN; Imthiajali S; Lakshminarayan Reddy T; Pushpavalli SN; Shankaraiah N; Pal-Bhadra M
    Bioorg Med Chem; 2013 Sep; 21(17):5198-208. PubMed ID: 23849207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activities of topopyrones.
    Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
    J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
    Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor.
    Jun KY; Kwon H; Park SE; Lee E; Karki R; Thapa P; Lee JH; Lee ES; Kwon Y
    Eur J Med Chem; 2014 Jun; 80():428-38. PubMed ID: 24796883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.